Hereditary hemorrhagic telangiectasia (HHT) is a potentially life-threatening genetic vascular disorder caused by loss-of-function mutations in the genes encoding activin receptor-like kinase 1 (ALK1), endoglin, Smad4, and bone morphogenetic protein 9 (BMP9). Injections of mouse neonates with BMP9/10 blocking antibodies lead to HHT-like vascular defects in the postnatal retinal angiogenesis model. Mothers and newborns share the same immunity through the transfer of maternal antibodies during breastfeeding. Here, we investigated whether the transmammary delivery route could improve the ease and consistency of administering anti-BMP9/10 antibodies in the postnatal retinal angiogenesis model. We found that anti-BMP9/10 antibodies, when intraperitoneally injected into lactating dams, are efficiently transferred into the circulation of breastfed neonatal pups. Strikingly, pups receiving anti-BMP9/10 antibodies via breastfeeding displayed consistent and robust vascular pathology in the retina, which included hypervascularization and defects in arteriovenous specification, as well as the presence of multiple and massive arteriovenous malformations. Furthermore, RNA-Seq analyses of neonatal retinas identified an increase in the key pro-angiogenic factor, angiopoietin-2, as the most significant change in gene expression triggered by the transmammary delivery of anti-BMP9/10 antibodies. Transmammary-delivered BMP9/10 immunoblocking in the mouse neonatal retina is therefore a practical, noninvasive, reliable, and robust model of HHT vascular pathology.
INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT)-also known as Rendu-Osler-Weber syndromeis an autosomal dominant genetic disease affecting approximately 1 in 5,000-10,000 individuals 1, 2 . HHT is characterized by the presence of vascular anomalies in multiple tissues and organs in the form of arteriovenous malformations (AVMs) and mucocutaneous telangiectases 3, 4 .
These vascular anomalies are structurally compromised and fragile, and hence are susceptible to rupture and hemorrhage. Telangiectases on the skin and in the nasal, oral, and gastrointestinal mucosa, as well as AVMs in the brain, lungs, and liver are typical in the clinical presentation of HHT 3, 4 . Genetic studies have revealed that most HHT patients carry mutations in the genes ENG (encoding endoglin) or ACVRL1 (activin receptor-like kinase 1, ALK1), which define the two disease subtypes HHT1 and HHT2, respectively 5 
. Mutations in SMAD4
(encoding Smad4) and GDF2 (bone morphogenetic protein 9, BMP9) were also found to cause rare forms of juvenile polyposis/HHT combined syndrome and HHT-like vascular anomaly syndrome, respectively 5 . Strikingly, BMP9, endoglin, ALK1, and Smad4 all functionally interact in, and are key mediators of, the same BMP receptor signaling pathway. ALK1 is a BMP type I Ser/Thr kinase receptor of the transforming growth factor-β superfamily, which forms functional complexes with a BMP type II receptor (e.g., BMPRII) and the co-receptor endoglin. BMP9 and BMP10 were identified as the specific and physiological ligands for ALK1 in endothelial cells [6] [7] [8] [9] .
Upon binding to ALK1-endoglin receptors, BMP9 and BMP10 activate the phosphorylation of receptor-regulated Smads (Smad1, Smad5, and Smad9) to facilitate the formation of Smad1/5/9-Smad4 complexes, which translocate into the nucleus to act as transcription factors in specific gene expression programs 10, 11 .
The exact mechanisms driving HHT pathogenesis remain unknown. However, recent evidence strongly suggests that the disease is caused by abnormal activation of angiogenesis, a process causing excessive endothelial cell proliferation and hypervascularization, which ultimately leads to the development of AVMs 12 . Indeed, ALK1 and endoglin are predominantly expressed by endothelial cells and BMP9/10 signaling is required for proper vascular development and maintenance, as well as for controlling transcriptional responses critically involved in angiogenesis, such as Notch and Wnt signaling pathways [13] [14] [15] [16] .
Studies in cell lines and animal models have demonstrated that HHT mutations cause haploinsufficiency. Indeed, transfection experiments showed that HHT mutations in either ALK1 or endoglin blocked activation of Smad1/5/9 signaling by BMP9 [17] [18] [19] . The notion that HHT is caused by loss-of-function mutations was strengthened by studies in mouse models showing that Acvrl1 or Eng deficiency, or injection of ALK1 extracellular domain-derived ligand trap (ALK1-Fc), led to vascular hyperproliferation and AVMs 20 . It is important to note that the AVMs in these models were consistently and robustly observed when Acvrl1 or Eng was completely deleted or inhibited, and when precipitating events were in place, such as angiogenesis or inflammation, a process referred to as the double or multiple hit hypothesis 20, 21 . Consistent with these observations, simultaneous neutralization of BMP9 and BMP10 in the postnatal retinal angiogenesis model [by injection of anti-BMP10 antibodies (Abs) into BMP9 knockout (KO) mice, or by co-injection of anti-BMP9 and anti-BMP10 Abs into wild type mice] led to hypervascularization 22, 23 , a vascular defect that was also observed in Acvrl1 or Eng conditional KO models and thus is reminiscent of HHT pathology 20 .
The postnatal retinal model is commonly used to study physiological or pathological angiogenesis during vascular development. Indeed, the newborn mouse retina is avascular and blood vessels rapidly develop during the first 2 weeks of life through angiogenesis 24 . This developmental characteristic offers a unique opportunity to study and/or manipulate vascular development, maintenance, and remodeling. In order to improve the BMP9/10 neutralization retinal angiogenesis model, we tested whether the natural transmammary delivery route for administration of BMP9/10 blocking Abs could replace the stressful, cumbersome, and poorly reliable step of individually injecting large numbers of pups.
Neonatal immunity is controlled by passive immunoglobin transfer from the mothers to their newborns during breastfeeding. This mechanism of transmammary delivery of Abs can be very efficient because Abs survive the gastrointestinal tract of the neonates to be absorbed into the blood circulation 25 . Here we report that BMP9 and BMP10 blocking Abs are efficiently transferred from the dam's circulation into the blood of their breastfed neonates to generate a consistent and robust retinal vascular pathology, which was characterized by the presence of key HHT vascular defects. Thus, delivery of BMP9/10 blocking Abs to neonatal pups via breast milk produces a practical, noninvasive, reliable, and robust model of HHT vascular pathology.
RESULTS

Transmammary transfer of BMP9 and BMP10 blocking Abs into the circulation of
breastfed mouse neonates. BMP9 and BMP10 are required, and have overlapping functions, during vascular development in the retina. Consequently, simultaneous injections of BMP9 and BMP10 blocking Abs directly into mouse neonates between postnatal day 1 (P1) and P4 was previously shown to induce strong retinal hypervascularization starting at P5 22, 23 . In an effort to improve the ease and consistency of administering Abs to large cohorts of neonates, we investigated whether delivery via the transmammary route was suitable for BMP9/10 neutralization in the retinal angiogenesis model. In this context, we first asked whether BMP9 and BMP10 blocking Abs could transfer from the dams' blood circulation to the blood of their breastfed neonates. To this end, lactating dams were injected intraperitoneally on P3 with monoclonal Abs specific for BMP9 (IgG2b, 15 mg/kg) and BMP10 (IgG2a, 15 mg/kg). As controls, separate sets of dams were injected with the same amount of isotype control IgG2b and IgG2a Abs, or with vehicle only (phosphate-buffered saline, PBS). At P6, neonates were euthanized and the levels of IgG2a and IgG2b Abs in their serum were analyzed by specific anti-IgG2a and anti-IgG2b ELISAs, respectively. We found that neonates breastfed by mice injected with either anti-BMP9/10 Abs or control IgGs showed a significant and consistent ~3fold increase in serum IgG2a concentration (which corresponds to an elevation of ~40 μg/mL), when compared to PBS-treated controls ( Fig. 1A ). An elevation in IgG2b Abs in these neonate serum samples was not detected using the anti-IgG2b ELISA ( Fig. 1B) . Baseline serum concentrations for IgG2b Abs were of ~200 μg/mL ( Fig. 1B) , which was approximately 10-fold higher than baseline serum IgG2a levels (~20 μg/mL, Fig. 1A ). We believe that these higher levels of baseline IgG2b in neonate serum could have masked any elevation of the concentration of this isotype after the transmammary transfer of IgGs. In this context, we developed an ELISA aimed at specifically detecting anti-BMP9 IgGs in the mouse serum (see 
Gene expression changes in whole retinas and HUVECs after ALK1 signaling inhibition.
Genome-wide transcriptomic analyses by RNA-Seq were employed to determine whether transmammary-delivered BMP9/10 immunoblocking affects gene expression in the whole retina.
Gene expression profiles were analyzed in 6 retinas obtained from neonates following transmammary transfer of anti-BMP9/10 Abs or control IgG2a/2b Abs (n = 6 mice for each group). This screen identified 128 genes with significant expression changes (FDR ≤ 1%, absolute log2 fold change ≥ 0.7, Fig. 4A and Table S1 ). Notably, in BMP9/10-immunoblocked retinas, we found a significant increase in the expression of Angpt2 (first hit when sorting by adjusted P-values, log2 fold change = 0.71, adjusted P = 2.69E-08, Limma Voom test, Table 1 and Fig. 4A ). Angpt2 codes for angiopoietin-2 (Ang2), a master regulator of sprouting angiogenesis 28 that was previously reported to be elevated at the transcriptional level in ALK1 deficient mice 29, 30 . Expression of genes coding for several collagen subunits, including Col4a1 To confirm the effect of ALK1 inhibition on global gene expression and to determine which deregulations originate from endothelial cells, we also performed RNA-Seq on human umbilical vein endothelial cells (HUVECs) treated or not with the ligand trap ALK1-Fc.
Comparison of the gene expression profiles obtained from BMP9/10-immunoblocked neonatal retinas and ALK1-Fc-treated HUVECs validated the increase of Ang2 expression upon ALK1 signaling inhibition. Indeed, ALK1-Fc treatment significantly increased of ANGPT2 RNA expression in HUVECs (log2 fold change = 0.32, adjusted P = 2.99E-06). These results are important because they confirmed that ALK1 signaling is an endogenous repressor of Ang2 expression in endothelial cells. In order to confirm at the protein level the effect of ALK1 signaling inhibition on Ang2 expression, we analyzed Ang2 levels by western blot (WB) in ALK1-Fc-treated HUVECs. As expected, we found that ALK1-Fc treatment strongly suppressed ALK1 signaling, which was manifested by a decrease in the activating phosphorylation of Smad1/5/9 and in the protein levels of inhibitor of differentiation 1 (ID1), two downstream targets and effectors of ALK1 activation (Figs. 4B and C). Importantly and in line with the RNA-Seq data, we further found that ALK1-Fc treatment of HUVECs significantly increased Ang2 protein levels (Figs. 4B and C). Together these results show that, at the autonomous level in endothelial cells, ALK1 signaling negatively controlled the expression of the key pro-angiogenic mediator Ang2.
Consequently, inhibition of ALK1 signaling in the presented model triggered a pathological proangiogenic response that led to hypervascularization and AVMs.
DISCUSSION
The first HHT mouse models developed were constitutive Acvrl1 and Eng KO mice. Based on the loss-of-function mutation paradigm in HHT, heterozygous KO mice for Acvrl1 or Eng were expected to exemplify the most representative models for this disease. However, Acvrl1 +/and Eng +/mice only displayed a mild phenotype with variable HHT-like vascular defects from one genetic background to another 20 . More recently, powerful inducible conditional KO mice for Acvrl1 or Eng were generated 26, 33, 34 . Complete knockdown of either Acvrl1 or Eng in these models led to more robust and reliable phenotypes, which included the appearance of HHT-like AVMs 20 . It is important to note that in these models, complete Acvrl1-or Eng-deficiency per se was found not to be sufficient for generating the observed vascular defects and that additional triggers in the form of inflammatory and/or angiogenic stimuli were required at the sites where AVMs developed 20, 21, 26 . Together with the observation that homozygous Acvrl1 or Eng KO mice die at an early embryonic stage most likely from angiogenesis defects, these data highlight the existence of a clear interplay between angiogenesis and ALK1-endoglin signaling. Evidence is indeed strong to indicate that ALK1-endoglin signaling is necessary for the proper expression of angiogenesis in certain tissues, and that angiogenic stimuli, in return, can provide a trigger for the development of HHT phenotypes in models defective for ALK1-endoglin signaling. For instance, treatments with the master initiator of sprouting angiogenesis VEGF 35 facilitated the development of vascular dysplasia in Acvrl1 and Eng KO mice 36, 37 , and VEGF neutralization using bevacizumab was found to be very effective at interfering with AVM development and progression in the wound-induced AVM mouse model 38 . These observations are in line with several early-phase clinical trials supporting that bevacizumab treatments-using topical, submucosal, or i.v. infusion routes-were effective at reducing epistaxis in HHT patients [39] [40] [41] .
In this context, the postnatal retinal angiogenesis model is very attractive for studying HHT vascular pathology. Indeed, physiological angiogenesis, which is required for postnatal vascular development, will provide the required additional trigger for vascular pathology development in mice deficient for ALK1 or endoglin expression 33, 42 or in mice treated with BMP9/10 blocking Abs 22, 23 . An important advantage of this model is the rapid pathology occurrence during the first week of postnatal vascular development. In addition, this model limits handling of newborn mice and their invasive manipulation. The use of BMP9/10 blocking Abs provides an additional advantage-over Acvrl1 or Eng KO mice-which is that Abs can be injected into any mouse strain, avoiding the phenotypic variability sometimes observed between mutant mice of different and complex genetic backgrounds 20 .
For these reasons and in the current study, we sought to improve the practicality and reliability of the BMP9/10 immunoblocking neonatal retinal angiogenesis model. Based on strong supporting literature showing that neonatal immunity is controlled by passive immunoglobin transfer from mothers to their newborns during breastfeeding, we asked whether the transmammary route could be used to deliver BMP9/10 blocking Abs into neonatal mice. We found for the first time that these Abs were very efficiently transferred from the dam's circulation to the neonates' blood during breastfeeding. In addition, this transfer triggered the development of a robust and consistent retinal vascular pathology, which included hypervascularization, partial loss of arteriovenous specification, and most importantly, AVMs.
Using whole transcriptome analyses in the neonatal retina, we further revealed in this study a significant elevation of Ang2 expression following anti-BMP9/10 Ab transmammary delivery. Whole transcriptome analyses of ALK1-Fc-treated HUVECs confirmed the effect of ALK1 signaling inhibition on Ang2 expression and also showed that ALK1 inhibition increased Ang2 expression in an endothelial cell-autonomous manner. WB analyses of ALK1-Fc-treated HUVECs confirmed that inhibiting ALK1 signaling significantly increased Ang2 protein levels.
Together, these data demonstrate that ALK1 signaling is a physiological repressor of Ang2 expression in endothelial cells. This observation is consistent with previous data showing that Ang2 expression is increased in ALK1 -/embryos 29 and adult ALK1 +/lung tissue 30 , as well as in conditional ALK1 KO mouse models of central nervous system AVMs 43 . Increases in Ang2 expression were also reported in the plasma and plexiform lesions of patients affected by pulmonary arterial hypertension (PAH), a condition that can be caused by mutations in ALK1 or BMPRII 44 . These data, however, contrast with the observation that Ang2 levels might be reduced in the plasma of a small cohort of HHT2 patients, but not in HHT1 patients 45 . In this context, our data strengthen the concept that Ang2 might be a crucial trigger for the vascular pathology caused by ALK1 signaling loss-of-function, and beyond that, for HHT pathogenesis.
Ang2 is a circulating ligand that, in conjunction with VEGF signaling, has critical pro-angiogenic properties during the induction of vascular sprouting 46 . Knowing that Ang2 is currently being investigated as a potential target for anti-angiogenic tumor therapy 47 , it is tempting to speculate that anti-Ang2 approaches might also have therapeutic value in HHT.
A gene that also showed deregulated expression, albeit with less consistency inside the groups, was Ccm2 (log2 fold change = 2.44, adjusted P = 1.72E-04, see Table S1 ). Ccm2 is of interest because it codes for malcavernin, a protein that mediates interactions between blood vessel cells. Mutations have been identified in the orthologous CCM2 human gene in patients with familial cerebral cavernous malformation (CCM) 48 . CCM leads to vascular malformations mostly in the brain, but also in other tissues, and its phenotype is closely related to, albeit different from, the AVMs observed in HHT patients: CCMs are low-flow lesions, while HHT AVMs are high-flow lesions 49 . Furthermore, while loss-of-function mutations in CCM2 are associated with CCM in humans, in our model of BMP9/10-immunoblocking, we observed an increase of Ccm2 expression, suggesting the possible existence of a compensatory mechanism that mitigates the vascular changes induced by ALK1 signaling inactivation. Further studies will be required to address this possible mechanism and determine whether CCM2 deregulations might also be associated with AVM development in HHT.
In conclusion, we propose that transmammary-delivered immunoblocking of BMP9 and BMP10 in the mouse neonatal retina is a practical, noninvasive, reliable, and robust model to study HHT pathogenesis. Furthermore, this study provides proof-of-concept data that the described model is suitable for mechanistic and ultimately, pre-clinical therapeutic investigations for HHT. From a more general standpoint and to the best of our knowledge, the paradigm described here represents the first example of generation of an infection-unrelated disease model utilizing mother/neonate-shared immunity.
MATERIALS AND METHODS
Mice
All animal procedures were performed in accordance with protocols approved by the Feinstein Institute for Medical Research Institutional Animal Care and Use Committee. Timed-pregnant C57BL/6J mice (3-4 month old) were used in this study (The Jackson Laboratory).
Antibody (Ab) injections and transmammary transfer of antibodies via lactation
Lactating dams were injected i.p. on P3 with PBS, mouse monoclonal isotype control Abs (15 mg/kg, IgG2b, MAB004; 15 mg/kg, IgG2a, MAB003; R&D Systems), or mouse monoclonal anti-BMP9 and anti-BMP10 Abs (15 mg/kg, IgG2b, MAB3209; 15 mg/kg, IgG2a, MAB2926; R&D Systems, respectively). Breastfed neonates were euthanized by CO 2 asphyxiation on P6 and non-heparinized blood was collected. Neonates were enucleated and eyes fixed in 4% paraformaldehyde for 20 min on ice and retinas were isolated.
Measurements of antibody levels by ELISA in neonatal mouse serum
ELISAs were used to measure IgG2a, IgG2b, and anti-BMP9 Ab levels in mouse serum. IgG2a 
Retinal whole mount immunohistochemistry (IHC)
IHC was performed using the previously described protocol 50 with the following modifications.
After fixation using 4% paraformaldehyde, retinas were dissected, cut four times to flatten them into petal flower shapes, and fixed with methanol for 20 min on ice. After removing methanol, retinas were washed in PBS for 5 min on a shaker at RT, and blocked in blocking solution (0.3% Triton, 0.2% BSA in PBS) for 1 h on a shaker at RT. Retinas were then incubated in isolectin GS-IB4 Alexa Fluor 488 (I21411, Molecular Probes) diluted 1:100 in blocking solution on a shaker overnight at 4°C. Retinas were then washed four times in 0.3% Triton in PBS for 10 min on a shaker, followed by two washes in PBS for 5 min on a shaker before mounted with Vecta Shield (H-1000, Vector Laboratories).
Blue latex perfusion assay
The blue latex perfusion assay was performed using a previously described protocol 26 , with the following modifications. Briefly, after euthanasia, neonate thoraxes were opened using Dumont #5 forceps and extra fine Bonn scissor (Fine Science Tools Inc.), the right atriums were cut using a Vannas spring scissor (Fine Science Tools Inc.), and the left ventricles were injected manually with 1 mL Blue latex (BR 80B, Connecticut Valley Biological Supply) using an insulin syringe U-100 (329652, BD Biosciences). After perfusion, eyes were enucleated and fixed, and retinas were dissected for microscopic observation as described above.
Image acquisition and analysis
Images for the analysis of the vascular network density were acquired using a laser confocal microscopy Olympus FV300, while images for the analysis of the number of crosses of arteries and veins were acquired using a Nikon Eclipse T2000-S microscope. Quantifications were performed using ImageJ. The analysis of the vascular network density was performed on a total of 6 mice per condition (PBS, isotype control, and anti-BMP9/10 Abs). Using a 20x lens, images 
Statistical analysis
ANOVA was used to assess statistical significance within multiple comparisons analyses. When data had non-normal distribution, Kruskal-Wallis test was performed instead. Tukey's or Dunn's multiple comparisons test were performed as post hoc tests. In all cases GraphPad Prism version 6.0 was used.
Retinal RNA extraction and sequencing
After euthanasia, neonate eyes were enucleated and retinas dissected in PBS. Retinas were rapidly dried with absorbent paper, snap-frozen in liquid nitrogen and stored at -80°C. RNA was then extracted from retinas using the RNeasy Micro Kit (Qiagen) according to the manufacturer's instructions. Total RNA quality was verified using Thermo Scientific NanoDrop and Agilent Bioanalyzer. RNA was then processed for RNA-Seq at the Genomics Resources Core Facility, Weill Cornell Medical College, New York, NY. Briefly, cDNA conversion and library preparation were performed using the TrueSeq v2 Illumina library preparation kit, following manufacturers' recommended protocol. Samples were multiplexed 6 per lane and sequenced on an Illumina HiSeq 4000 instrument.
RNA-Seq data analysis
Reads were uploaded to the GobyWeb system 51 and aligned to the 1000 genome human reference sequence 52 with the STAR aligner 53 . Ensembl annotations for transcripts were obtained from Biomart and Ensembl automatically using GobyWeb. Annotations were used to determine read counts using the Goby alignment-to-annotation-counts mode 54 , integrated in GobyWeb in the differential expression analysis with EdgeR plugin. Counts were downloaded from GobyWeb as a tab delimited file and analyzed with MetaR 55 . Statistical analyses were conducted with Limma Voom 56 , as integrated in MetaR 1.7.2, using the rocker-metar docker image version 1.6.0.1. P-values were adjusted for multiple testing using the False Discovery Rate method 57 . Heat maps were constructed with MetaR, using the pheatmap R package.
Gene annotations were determined with Ensembl/Biomart, using the biomart micro-language in MetaR 55 . MetaR analysis is shown in supplementary material.
HUVEC cultures, treatments, RNA extraction, and western blot (WB) analyses
HUVECs were isolated from anonymous umbilical veins, as described before 58 . HUVECs were subcultured using a trypsin/EDTA-reagent pack (Lonza) and maintained in endothelial cell growth media (Sciencell). Cells were treated or not for 24 h with 1 μg/mL ALK1-Fc (R&D Systems). Cells were then rinsed with PBS and processed for RNA extraction and RNA-Seq as described above. For WB analyses, cells were processed as before 59 with the following modifications. Cells were solubilized in RIPA buffer (EMD Millipore) supplemented with 1× Complete protease inhibitor mixture (Roche Applied Science). 5-20 μg of proteins (depending on the primary antibody used) were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Membranes were then probed with Abs directed against phospho-Smad1/5/9 (Cell Signaling Technology), total Smad5 (Cell Signaling Technology), ID1 (BioCheck), Ang2 (Santa Cruz Biotechnology), and actin (BD Transduction Laboratories). A standard ECL detection procedure was then used. 
